| Name | Farampator |
| Description | Farampator (CX-691) (CX-691;Org24448) is a positive modulator of AMPA receptor. |
| In vitro | CX691 attenuates a scopolamine-induced impairment of cued fear conditioning following acute administration (0.1 mg/kg p.o.) and a temporally induced deficit in novel object recognition following both acute (0.1 and 1.0 mg/kg p.o.) and sub-chronic (bi-daily for 7 days) administration (0.01, 0.03, 0.1 mg/kg p.o.). It also improves attentional set-shifting following sub-chronic administration (0.3 mg/kg p.o.). Farampator (500 mg) unequivocally improves short-term memory but appeares to impair episodic memory. Furthermore, it tends to decrease the number of switching errors in the CTMT. Drug-induced side effects (SEs) included headache, somnolence and nausea. Subjects with SEs has significantly higher plasma levels of farampator than subjects without SEs. Farampator has potential in treating disorders characterised by cognitive deficits such as Alzheimer's disease and schizophrenia. |
| In vivo | Farampator holds promise for managing cognitive deficits associated with conditions like Alzheimer's disease and schizophrenia. It mitigates scopolamine-induced cued fear conditioning impairment with a single dose (0.1 mg/kg p.o.) and rectifies deficits in novel object recognition after both acute (0.1 and 1.0 mg/kg p.o.) and sub-chronic (twice daily for 7 days at doses of 0.01, 0.03, 0.1 mg/kg p.o.) administrations. Moreover, farampator enhances attentional set-shifting with sub-chronic use (0.3 mg/kg p.o.)[1]. Notably, at a 500 mg dosage, farampator consistently improves short-term memory, albeit with a tendency to impair episodic memory and reduces switching errors in the CTMT. Reported side effects (SEs) include headache, somnolence, and nausea, with subjects exhibiting SEs displaying significantly higher plasma levels of farampator compared to those without SEs[2]. |
| Storage | Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | 10% DMSO+40% PEG300+5% Tween 80+45% Saline : 2 mg/mL (8.65 mM), Sonication is recommended.
DMSO : 50 mg/mL (216.22 mM), Sonication is recommended.
|
| Keywords | Org-24448 | Org 24448 | Ionotropic glutamate receptors | Inhibitor | inhibit | iGluR | Farampator | CX691 | CX 691 | AMPA |
| Inhibitors Related | Urethane | Decanoic Acid | N-Methylsarcosine | L-Glutamic acid | N,N-Dimethylglycine hydrochloride | L-Phenylalanine | glycine | Indole-2-carboxylic acid | L-Glutamine | L-Glutamic acid monosodium salt | Memantine | Memantine hydrochloride |
| Related Compound Libraries | Target-Focused Phenotypic Screening Library | Bioactive Compound Library | Anti-Neurodegenerative Disease Compound Library | Antidepressant Compound Library | Membrane Protein-targeted Compound Library | Glutamine Metabolism Compound Library | Anti-Cancer Clinical Compound Library | Drug Repurposing Compound Library | NO PAINS Compound Library | Bioactive Compounds Library Max | Ion Channel Targeted Library | Anti-Cancer Drug Library |
United States
